To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.
To collect and characterise the incidence of adverse events related to the safety specifications\*1 of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA. This investigation will be conducted for application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law. \*1: Bone marrow depression, interstitial lung disease, new primary malignancies, and embryofoetal toxicity
Study Type
OBSERVATIONAL
Enrollment
130
Incidence of adverse events related to the safety specifications
Safety specifications:Bone marrow depression, interstitial lung disease, new primary malignancies, and embryofoetal toxicity
Time frame: from baseline to 1year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Osaka, Lyn010001, Japan
Research Site
Kanagawa, Lyn010003, Japan
Research Site
Okayama, Lyn010004, Japan
Research Site
Akita, Lyn010005, Japan
Research Site
Niigata, Lyn010006, Japan
Research Site
Shizuoka, Lyn010007, Japan
Research Site
Niigata, Lyn010008, Japan
Research Site
Tokyo, Lyn010009, Japan
Research Site
Saitama, Lyn010010, Japan
Research Site
Aichi, Lyn010011, Japan
...and 50 more locations